drugset
drugset / Trial / NCT04826172

Exploratory Study on the Safety, Tolerability, and Pharmacodynamics of IMB-1018972 in Subjects With Angina Due to Obstructive Coronary Artery Disease (IMPROVE-Ischemia)

NCT04826172 ↗

Phase 2 Completed 58 enrolled Imbria Pharmaceuticals, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to assess the safety and tolerability of IMB-1018972 in subjects with obstructive CAD and inducible ischemia.

Timeline

Start
2021-04-23
Primary completion
2023-09-21
Completion
2023-09-21

Outcome

Met primary endpoint

release “The IMPROVE-ISCHEMIA Phase 2 clinical trial met the primary endpoint of tolerability and safety” imbria.com ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Ninerafaxstat Small molecule 200 mg Oral

Indications

coronary artery disorder ischemic disease